Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,404 across all filing types
Latest filing 2018-09-04 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TOTAL VOTING RIGHTS
Regulatory Filings
2018-09-04 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is explicitly labeled with an 'RNS Number' and states that the information is provided by 'RNS, the news service of the London Stock Exchange.' The content concerns 'Voting Rights and Capital' as of a specific date (31 August 2018) and references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of mandatory, brief regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K or ER) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2018-09-03 English
ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE
Regulatory Filings
2018-08-31 English
AstraZeneca Update on Anifrolumab in SLE
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and is dated August 31, 2018. It announces 'top-line results' from a Phase III clinical trial (TULIP 1) for a drug (anifrolumab) and states that the trial 'did not meet the primary endpoint.' This content is a specific update regarding clinical trial progress, which is typically released via regulatory news services. Since it is an announcement of specific, material, non-financial news that doesn't fit into ER (Earnings Release), IR (Interim Report), or LTR (Legal Proceedings), the most appropriate classification is RNS (Regulatory Filings), which serves as the general regulatory announcement category for material news not covered elsewhere. The document length (7741 chars) is substantial, but the nature is a direct announcement of a trial outcome, not a full report or presentation.
2018-08-31 English
EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES
Regulatory Filings
2018-08-30 English
EC approves Bydureon BCise device for T2 diabetes
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 2395Z' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority to act as a Primary Information Provider. The content is a press release announcing the European Commission's approval of a new drug formulation. This format—a brief, time-sensitive announcement disseminated via an official regulatory news service (RNS)—is characteristic of a general regulatory filing that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (5112 chars) is substantial enough that it is not just a placeholder announcement (RPA), but a substantive regulatory news item.
2018-08-30 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.